Compare
Amgen vs Cytokinetics (AMGN vs CYTK)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and Cytokinetics (CYTK) -9.3%; so far this year the figures are +40.7% and -15.5%.
Amgen is the larger company by market value, about 33.3 times the size of Cytokinetics.
Revenue grew +8.2% at AMGN and +29.9% at CYTK over the last year.
AMGN yields 2.16%. CYTK pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | CYTK | |
|---|---|---|
| Price | $460.42 | $53.69 |
| 1-day | +0.03% | -3.35% |
| YTD | +40.67% | -15.50% |
| 1 year | +43.94% | -9.29% |
| 3 years | +76.51% | +52.96% |
| Market cap | $249.1B | $7.5B |
| P/E | 26.7 | — |
| P/S | 6.40 | 66.02 |
| P/B | 17.35 | — |
| Revenue growth | +8.20% | +29.90% |
| EPS growth | +33.30% | — |
| Gross margin % | 70.9 | — |
| Net margin % | 24.1 | -686.6 |
| ROE % | 65.4 | — |
| Debt / equity | 3.76 | — |
| FCF yield % | 3.8 | -7.9 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 0.99 |
| RSI (14) | 60.5 | 27.0 |
| Technical rating |